Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
70 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
Rank Status Study
21 Recruiting A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Conditions: Solid Tumors;   Soft-tissue Sarcoma;   Breast Cancer
Interventions: Drug: Cyclophosphamide and JX-594 dose escalation;   Drug: Cyclophosphamide and JX-594;   Drug: Cyclophosphamide
22 Recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
23 Recruiting Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis
24 Not yet recruiting Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MEDI4736 (Anti PD-L1);   Drug: Placebo;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide
25 Unknown  The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: gefitinib
26 Recruiting Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
Condition: Operable Breast Cancer
Intervention: Drug: 0.5% lignocaine 60mM
27 Recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
28 Recruiting A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin;   Drug: Placebo
29 Unknown  ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Conditions: Breast Cancer;   Breast Disease;   Neoplasms;   Neoplasms by Site
Intervention: Drug: cyclophosphamide, Adriamycin, Docetaxel, Trastuzumab, Zolendronic acid
30 Recruiting Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Stereotactic body radiotherapy ( SBRT)
31 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
32 Recruiting Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Anastrozole+Fulvestrant;   Drug: Tamoxifen
33 Recruiting Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ductal Breast Carcinoma In Situ;   Lobular Breast Carcinoma In Situ;   Stage 0 Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Drug: Telapristone Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
34 Recruiting Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil™ in Advanced Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Biological: Vigil™;   Drug: Durvalumab (MEDI4736)
35 Recruiting Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms;   Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib;   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis
36 Recruiting Persistent Organic Pollutants and Breast Cancers (POPCASE)
Condition: Breast Cancer
Interventions: Procedure: Breast cancer surgery;   Procedure: plastic surgery
37 Recruiting Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Conditions: Squamous Cell Cancer of Head and Neck;   Triple Negative Breast Cancer;   Epithelial Ovarian Cancer;   Malignant Melanoma;   Advanced Solid Tumors
Intervention: Drug: Pembrolizumab
38 Recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
39 Not yet recruiting Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Postmenopausal;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Alisertib;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis
40 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years